Ireland· IE-PA-PA23142/014/001
Eyreida 0.3 mg/ml eye drops, solution
A bimatoprost product containing bimatoprost, registered in Ireland by Aspire Pharma (Malta) Limited. The same ATC class is registered in 19 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Bimatoprost is registered in 19 of 19 countries.
Countries holding a registration under ATC S01EE03 (bimatoprost), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 11 of them publish a price we can compare per daily dose
Bimatoprost · ATC S01EE03
19 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- Bimatoprost
- Manufacturer
- Aspire Pharma (Malta) Limited
- Country
- Ireland (IE)
- ATC code
- S01EE03
- ATC class
- Bimatoprost
- Defined daily dose
- 0.1 ml, AT
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA23142/014/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
89 interactions on record for bimatoprost.
Graded by severity as the source publishes them — 89 info. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Bimatoprost · interactions on record
89 records
Same medicine, other countries
Bimatoprost in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesbimatoprostAlembic Pharmaceuticals Limited
- CzechiaBIMATOPROST FARMAPROJECTSFarmaprojects S.A.U., Barcelona
- NetherlandsBIMAGAN 0,3 mg/ml oogdruppels, oplossingS.C. Rompharm Company S.R.L.
- FinlandBimatoprost AccordAccord Healthcare B.V.
- SwedenBimatoprost Brown & Burk 0,3 mg/ml Ögondroppar, lösning i endosbehållareBrown & Burk IR Limited
- BelgiumBimatoprost EG 0.3 mg/mlEG
- FranceAMIRIOX 0,3 mg/mL, collyre en solutionSIFI (ITALIE)
- PolandBimatoprost IndocoIndoco Remedies Czech s.r.o.
Authorised across Europe · EMA
The same active substance is authorised in 28 EEA countries. Names it is sold under:
- Austria · Bima-Vision Sine, Bimato-Vision
- Belgium · Bimatoprost Eg, Bimatoprost Eg (Eurogenerics)
- Bulgaria · Бимаган, Биматопрост Абр
- Cyprus · Bimatoprost Pharmathen, Birmost
- Czechia · Bimatoprost Farmaprojects, Bimatoprost Olikla
- Germany · Amiriox, Bimato-Vision
- Denmark · Bimatoprost "hexal", Bimatoprost "stada"
- Estonia · Elymbus
- Spain · Amiriox, Bamixol
- Finland · Bimatoprost, Bimatoprost Sandoz
- France · Amiriox, Bimatoprost
- United Kingdom (Northern Ireland) · Amiriox, Bimatoprost Alissa Healthcare Research
- Greece · Birmost, Dacrysan
- Croatia · Elymbus
- Iceland · Bimatoprost, Elymbus
- Italy · Amiriox, Bialviz
- Liechtenstein · Lumigan
- Lithuania · Bimican, Bimifree
- Luxembourg · Bimatoprost Eg, Bimatoprost Eg (Eurogenerics) Nv
- Latvia · Bimican, Bimifre
- Netherlands · Bimagan, Bimato-Vision
- Norway · Bimaprez, Bimatoprost Hexal
- Poland · Bimican, Bimifree
- Portugal · Amiriox, Bimatoprost Stulln
- Romania · Amiriox, Bimagan
- Sweden · Bimaprez, Bimatoprost
- Slovenia · Elymbus
- Slovakia · Bimatoprost Olikla, Elymbus
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/80a0f6aa-4619-411a-8554-4a3d8059f774 GET /v1/drugs/80a0f6aa-4619-411a-8554-4a3d8059f774?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Eye drops, solution",
"routes": [
"Ocular use"
],
"source": "hpra",
"atc_all": [
"S01EE03"
],
"strength": null,
"pa_number": "PA23142/014/001",
"substances": [
"Bimatoprost"
],
"legal_basis": "Hybrid application (Article 10(3) of Directive No 2001/83/EC)",
"market_info": "Not marketed",
"authorised_at": "08/11/2019",
"dispensing_status": "Product subject to prescription which may be renewed (B)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about bimatoprost.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.